{
  "companies": [
    {
      "company_name": "Krystal Biotech",
      "overview": "Krystal Biotech focuses on developing gene therapies for dermatological diseases. Their key asset, KB707, aimed at treating skin cancer, represents their commitment to innovative treatment solutions. Despite a promising start, the phase 2 study of KB707 was halted.",
      "location": null,
      "website": null,
      "therapeutic_areas": [
        "oncology"
      ],
      "clinical_trials": {
        "phase_2_failed": [
          {
            "nct_id": null,
            "title": "Phase 2 study of KB707",
            "condition_or_disease": "Skin Cancer",
            "intervention_name": "KB707",
            "phase": null,
            "status": "Halted",
            "sponsor": "Krystal Biotech",
            "why_stopped": "Not specified",
            "completion_date": null
          }
        ],
        "phase_3_failed": [],
        "dormant_assets": []
      },
      "drug_assets": [
        {
          "name": "KB707",
          "modality": "gene therapy",
          "indication": "Skin Cancer",
          "development_stage": "phase 2",
          "target": null
        }
      ],
      "decision_makers": [
        {
          "name": "Krish Krishnan",
          "role": "Chairman/CEO at Krystal Biotech, Inc. ...",
          "linkedin_url": "https://www.linkedin.com/in/krish-krishnan-3a0b43115",
          "email": null,
          "source": "serpapi"
        },
        {
          "name": "Suma Krishnan",
          "role": "Founder & President at Krystal Biotech, Inc.",
          "linkedin_url": "https://www.linkedin.com/in/suma-krishnan-781130116",
          "email": null,
          "source": "serpapi"
        },
        {
          "name": "David C.",
          "role": "Krystal Biotech, Inc.",
          "linkedin_url": "https://www.linkedin.com/in/davidchienmd",
          "email": null,
          "source": "serpapi"
        },
        {
          "name": "Andy Orth",
          "role": "Krystal Biotech, Inc.",
          "linkedin_url": "https://www.linkedin.com/in/andy-orth-87822a6",
          "email": null,
          "source": "serpapi"
        },
        {
          "name": "David Sweet MD, PhD",
          "role": "Director of Clinical Development at ...",
          "linkedin_url": "https://www.linkedin.com/in/dsweetmdphd",
          "email": null,
          "source": "serpapi"
        }
      ],
      "investors": [],
      "fit_score_for_convexia": 75,
      "reason_for_fit_score": "Krystal Biotech's halt in the phase 2 study of KB707 due to unspecified reasons, combined with their focus on oncology, presents a potential opportunity for Convexia to explore rescue strategies. The company's commitment to gene therapy for dermatological diseases aligns with Convexia's interest in innovative treatments with a strong scientific rationale.",
      "data_sources_used": [
        "https://www.oncologynewscentral.com/oncology/halted-trials-patient-deaths-and-more-recent-new-on-oncology-research-concerns"
      ],
      "last_updated": "2025-11-17 22:49:29.652197"
    }
  ],
  "total_companies": 1,
  "total_decision_makers": 5,
  "total_emails": 5
}